National Innovative Medicines Fund List

(Including live list of indications funded via the Innovative Medicines Fund with their commissioning criteria for use)

v1.12

01-Apr-25

National Innovative Medicines Fund (IMF) List

List

This list should be read in conjunction with all other available information found at: https://www.england.nhs.uk/medicines-2/innovative-medicines-fund/

Drug	Indication	Criteria for use	Available to new patients		Eligible for Interim Funding	Interim Funding agreed by manufacturer	IMF Managed Access Scheme	Expected Entry into Baseline Commissioning (if known)
			Yes	Yes (but notice of removal served)				
Etranacogene dezaparvovec	ETR1a- Initial Funding Application for treating moderately severe or severe haemophilia B (TA989) where the following criteria have been met:	1. The prescribing clinician confirms the patient is aged 18 years or older.	From 27-June-24		N/A	N/A	Yes	nca
		2. The prescribing clinician confirms the patient has moderately severe or severe haemophilia B						
		3. The prescribing clinician confirms the patient has a demonstrated absence of Factor IX inhibitors and no previous history of Factor IX inhibitors.						
		4. The prescribing clinician confirms a pre-existing neutralising antibody titre has been performed and that the patient does not have neutralising anti-AAV5 antibodies above a titre of 1:678 (7-point assay) or 1:898 (9-point assay).						
		5. The prescribing clinician confirms the patient's baseline hepatic function has been assessed.						
		6. The prescribing clinician confirms compliance with UKHCDO guideline, in particular the approval and pathway process and that treatment will be delivered by a commissioned haemophilia ATMP treatment hub.						
		7. The prescribing clinician confirms that use is in accordance with the SmPC and the managed access agreement, as detailed in NICE TA989.						
Etranacogene dezaparvovec	ETR1b-Post Infusion Funding Application for treating moderately severe or severe haemophilia B (TA989) where the following criteria have been met:	1.The prescribing clinician confirms that one of the following applies: - The patient remained eligible for treatment and was infused with etranacogene dezaparvovec - The patient was no longer eligible for treatment and the order was cancelled before acceptance of the product - The patient was no longer eligible for treatment and the order had to be cancelled after acceptance of the product - The product was destroyed following identification of a defect or latent defect (i.e. a fault occurring prior to receipt of product, regardless of when it was detected) - The product was destroyed following identification of other damage to the product Please enter the date of infusion with etranacogene dezaparvovec if option 1 applies, otherwise please enter '00/00/0000': _____	From 27-June-24		N/A	N/A	Yes	nca
		2. The prescribing clinician confirms that etranacogene dezaparvovec was otherwise used as set out in the SmPC and the managed access agreement as detailed in NICE TA989						

National Innovative Medicines Fund (IMF) List

Drug	Indication	Criteria for use	Available to new patients		Eligible for Interim Funding	Interim Funding agreed by manufacturer	IMF Managed Access Scheme	Expected Entry into Baseline Commissioning (if known)
			Yes	Yes (but notice of removal served)				
Exagamglogene autotemcel	EXA1a-Initial Funding Application (for each cell collection) – Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [TA1003] where the following criteria have been met:	1.The prescribing clinician confirms that one of the following applies: a. The prescribing clinician confirms the patient is 16 years and older, being treated in an adult service, and the centre is commissioned to deliver this treatment OR b. The prescribing clinician confirms the patient is 12-18 years old at the point of referral to the panel for approval, is being treated within a paediatric service, and the centre is commissioned to deliver treatment in this age group	From 08-August-24		N/A	N/A	Yes	nca
		2. The prescribing clinician confirms the patient has transfusion-dependent beta-thalassaemia (diagnosis confirmed by DNA technology) and is suitable for haematopoetic stem cell transplant but a human leukocyte antigen (HLA)- matched related haematopoietic stem cell donor is not available.						
		3. The prescribing clinician confirms that the patient has not received a prior allogeneic or autologous haematopoietic stem cell transplant.						
		4. The prescribing clinician confirms that approval for treatment has been obtained from the National Haemoglobinopathy Panel on: To enter date in the box as (00/00/0000) ----------						
		5. The prescribing clinician confirms that one of the following applies 5a.The prescribing clinician confirms this is the patients first mobilisation cycle* OR 5b. The prescribing clinician confirms this is the patients second mobilisation cycle* OR 5c. The prescribing clinician confirms this is the patients third mobilisation cycle* OR 5d. The prescribing clinician confirms this is the patients fourth mobilisation cycle* OR 5e. The prescribing clinician confirms this is the patients fifth mobilisation cycle* *One mobilisation cycle is defined as mobilisation plus the completion of all collective attempts at apheresis that may occur from Day 5 to Day 7 (inclusive).						
		6. The prescribing clinician confirms that use is in accordance with the SmPC and the managed access agreement, as detailed in NICE TA1003 .						
		7. The prescribing clinician confirms the required data will be collected as per the managed access agreement.						
Exagamglogene autotemcel	EXA1b-Funding Application (treatment outcome)– Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [TA1003] where the following criteria have been met:	1. The prescribing clinician confirms that one of the following applies: The patient remained eligible for treatment and was infused with exagamglogene autotemcel. The patient was no longer eligible for treatment and the order was cancelled before acceptance of the product. The patient was no longer eligible for treatment and the order had to be cancelled after acceptance of the product. The product was destroyed following identification of a defect or latent defect (i.e. a fault occurring prior to receipt of product, regardless of when it was detected). The product was destroyed following identification of other damage to the product	From 08-August-24		N/A	N/A	Yes	nca
		2.If option 1a applies, I confirm that Exagamglogene autotemcel was otherwise used as set out in the SmPC and the managed access agreement as detailed in NICE TA 1003 and please enter the date of infusion with Exagamglogene autotemcel, otherwise please enter '00/00/0000':						

National Innovative Medicines Fund (IMF) List

Drug	Indication	Criteria for use	Available to new patients		Eligible for Interim Funding	Interim Funding agreed by manufacturer	IMF Managed Access Scheme	Expected Entry into Baseline Commissioning (if known)
			Yes	Yes (but notice of removal served)				
Exagamglogene autotemcel	EXA2a-National Innovative Medicines Fund Application Form – Initial Funding Application (for each cell collection) – Exagamglogene autotemcel for treating sickle cell disease [ID4016] where the following criteria have been met:	1. To note, a separate Blueteq form should be submitted for use of plerixafor 1a. The prescribing clinician confirms the patient is 16 years and older, being treated in an adult service, and the centre is commissioned to deliver this treatment OR 1b. The prescribing clinician confirms the patient is 12-18 years old at the point of referral to the panel for approval, is being treated within a paediatric service, and the centre is commissioned to deliver treatment in this age group. 2.The prescribing clinician confirms the patient has sickle cell disease and has recurrent vaso-occlusive crises (VOCs) defined as at least 2 VOC's per year during the 2 previous years. To note: In the SmPC: Patients were eligible for the study if they had a history of at least 2 severe vaso-occlusive crisis events per year in the 2 years prior to screening, which were defined as: •an acute pain event •acute chest syndrome •priapism lasting at least 2?hours •splenic sequestration 3. The prescribing clinician confirms the patient has: a. βS/βS, βS/β+ or βS/β0 genotype, b. is suitable for haematopoetic stem cell transplant, c. and for whom a human leukocyte antigen (HLA)-matched related haematopoietic stem cell donor is not available. 5. The prescribing clinician confirms that approval for treatment has been obtained from the National Haemoglobinopathy Panel on: To enter date in the box as (00/00/0000) 5a.The prescribing clinician confirms this is the patients first mobilisation cycle* OR 5b. The prescribing clinician confirms this is the patients second mobilisation cycle* OR 5c. The prescribing clinician confirms this is the patients third mobilisation cycle* OR 5d. The prescribing clinician confirms this is the patients fourth mobilisation cycle* OR 5e. The prescribing clinician confirms this is the patients fifth mobilisation cycle* OR 5f. The prescribing clinician confirms this is the patients sixth mobilisation cycle* * One mobilisation cycle is defined as mobilisation plus the completion of all collective attempts at apheresis that occur from Day 1 to Day 3 (inclusive) 6. The prescribing clinician confirms that use is in accordance with the SmPC and the managed access agreement, as detailed in NICE TA ID4016 7. The prescribing clinician confirms the required data will be collected as per the managed access agreement	From 31-January-25		N\A	N\A	Yes	nca
Exagamglogene autotemcel	EXA2b-National Innovative Medicines Fund Application Form – Funding Application (treatment outcome) – Exagamglogene autotemcel for treating sickle cell disease [ID4016] where the following criteria have been met:	1. The prescribing clinician confirms that one of the following applies: a. The patient remained eligible for treatment and was infused with exagamglogene autotemcel. b. The patient was no longer eligible for treatment and the order was cancelled before acceptance of the product. c. The patient was no longer eligible for treatment and the order had to be cancelled after acceptance of the product. d. The product was destroyed following identification of a defect or latent defect (i.e. a fault occurring prior to receipt of product, regardless of when it was detected). e. The product was destroyed following identification of other damage to the product 2. If option 1a applies, the prescribing clinician confirmsthat Exagamglogene autotemcel was otherwise used as set out in the SmPC and the managed access agreement as detailed in NICE TA ID4016 and please enter the date of infusion with Exagamglogene autotemcel, otherwise please enter '00/00/0000':	From 31-January-25		N/A	N/A	Yes	nca

National Innovative Medicines Fund (IMF) List

Drug	Indication	Criteria for use	Available to new patients		Eligible for Interim Funding	Interim Funding agreed by manufacturer	IMF Managed Access Scheme	Expected Entry into Baseline Commissioning (if known)
			Yes	Yes (but notice of removal served)				
Fenfluramine	FEN1a – National Innovative Medicines Fund Application Form – Initial Funding Application- Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]	1.The prescribing clinician confirms the patient is aged 2 and over. 2.The prescribing clinician confirms the patient has seizures associated with Lennox–Gastaut syndrome. 3.The prescribing clinician confirms that fenfluramine is being used as an add-on to other antiseizure medicines. 4.The prescribing clinician confirms that the frequency of drop seizures will be checked every 6 months, and fenfluramine will be stopped if the frequency is not reduced by at least 30% compared with the 6 months before starting treatment. 5.The prescribing clinician confirms the patient will receive the licensed dose and frequency of fenfluramine in line with its marketing authorisation.	From 20-February-25		Yes	Agreed	No	24-Jun-25

National Innovative Medicines Fund (IMF) List

Drug	Indication	Criteria for use	Available to new patients		Eligible for Interim Funding	Interim Funding agreed by manufacturer	IMF Managed Access Scheme	Expected Entry into Baseline Commissioning (if known)
			Yes	Yes (but notice of removal served)				
Sodium thiosulfate	STS1_ver1.0 – National Innovative Medicines Fund Application Form – Sodium thiosulfate (as Pedmarqsi®) for the prevention of cisplatin-induced ototoxicity in paediatric patients with localised, non-metastatic solid tumours and aged 1 month or more and younger than 18 years	1.The prescribing clinician confirms that an application has been made and the first cycle of sodium thiosulfate (as Pedmarqsi®) will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy. 2.The prescribing clinician confirms that the patient is aged 1 month or more and younger than 18 years. Note: patients who are aged 18 years and older are not eligible to commence treatment with sodium thiosulfate. 3.The prescribing clinician confirms that the patient has a localised, non-metastatic solid tumour. Note: sodium thiosulfate is not licensed for use in patients with non-localised or metastatic solid tumours or in patients with haematological malignancy. 4.The prescribing clinician confirms that that the patient is having cisplatin-containing chemotherapy. Note: sodium thiosulfate is not licensed or funded for patients having chemotherapy with other platinum compounds (e.g. carboplatin). 5.The prescribing clinician confirms the use of the sodium thiosulfate has been discussed at an appropriate multi-disciplinary team (MDT) meeting 6.The prescribing clinician confirms that I understand all the critical timing issues relating to the administration of sodium thiosulfate in relation to cisplatin as set out in section 4.2 of the Summary of Product Characteristics (SPC) of sodium thiosulphate (as Pedmarqsi®). Note: Sodium thiosulfate as Pedmarqsi® is the only licensed formulation of sodium thiosulfate for use in this indication. 7.The prescribing clinician confirms that I understand that sodium thiosulfate (as Pedmarqsi®) is hypertonic and therefore the drug's SPC recommends that its administration is via a central line as set out in section 4.2 of the drug's SPC. 8.The prescribing clinician confirms that I understand the need to provide highly effective multi-agent intravenous anti-emetic treatment shortly before administration of sodium thiosulfate as set out in section 4.2 of the drug's SPC. 9.The prescribing clinician confirms that the patient has not previously received sodium thiosulfate for the prevention of cisplatin-induced ototoxicity unless the patient is continuing on sodium thiosulfate treatment previously commenced via a company early access scheme and all other treatment criteria on this from are complied with. 10.The prescribing clinician confirmsthat sodium thiosulfate (as Pedmarqsi®) will be otherwise used as set out in its SPC.	From 26-February-25		Yes	Agreed	No	22-Apr-25

National Innovative Medicines Fund (IMF) List

Drug	Indication	Criteria for use	Available to new patients		Eligible for Interim Funding	Interim Funding agreed by manufacturer	IMF Managed Access	Expected Entry into Baseline Commissioning (if
			Yes	Yes (but notice of removal				
Ruxolitinib	RUX3 – National Innovative Medicines Fund Application Form - Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over [ID6377]	1.The prescribing clinician confirms the patient is aged 12 years and over.	From 21-March-25		Yes	Agreed	No	30-Jul-25
		2. The prescribing clinician confirms the patient has acute graft versus host disease (GvHD).						
		3. The prescribing clinician confirms that the patient has had an inadequate response to corticosteroids						
		4. The prescribing clinician confirms the patient will receive the licensed dose and frequency of ruxolitinib in line with its marketing authorisation.						

National Innovative Medicines Fund (IMF) List

Drug	Indication	Criteria for use	Available to new patients		Eligible for Interim Funding	Interim Funding agreed by manufacturer	IMF Managed Access Scheme	Expected Entry into Baseline Commissioning (if known)
			Yes	Yes (but notice of removal served)				
Leniolisib	LENI1 – National Innovative Medicines Fund Application Form - Leniolisib for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over [ID6130]	1. The prescribing clinician confirms the patient is aged 12 and over and weighs 45 kg or greater 2. The prescribing clinician confirms the patient has Activated phosphoinositide 3-kinase (PI3K) delta syndrome (APDS) 3.The prescribing clinician confirms the patient will receive the licensed dose and frequency of leniolisib in line with its marketing authorisation	From 27-March-25		Yes	Agreed	Yes	Tbc

National Innovative Medicines Fund (IMF) List

Date published	Author(s)	Revision summary
n/a	D Dwyer	Initial draft of new IMF list, based on pre-existing national IMF list but updated for changes to the IMF, for review.
03/07/2024	S Patel; R Gowa; P Ryan; S Ahmed	Final version of new IMF list
19/08/2024	R Gowa; S Ahmed	1 drug/indication recommended for the IMF, 2 drugs/indications removed from the list
06/09/2024	R Gowa; S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding
22/10/2024	R Gowa; S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding
20/11/2024	R Gowa; S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding
06/12/2024	R Gowa; S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding, 1 drugs/indications removed from the list
20/12/2024	R Gowa; S Ahmed	0 drug/indication recommended for the IMF
23/12/2024	R Gowa; S Ahmed	1 drugs/indications removed from the list
31/01/2025	R Gowa; S Ahmed	1 drug/indication recommended for the IMF, 1 drugs/indications removed from the list
20/02/2025	S Mcaleer;S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding
27/02/2025	S Mcaleer;S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding
21/03/2025	S Mcaleer;S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding
01/04/2025	S Mcaleer;S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding

General or criteria changed	Summary of changes
Changes to version 1.0	
ETR1a_v1.0, ETR1b _v1.0	Recommended for the IMF
VOX1a_v1.0	Recommended for routine commissioning, receiving IMF interim funding
TAF1a _v1.0	Recommended for routine commissioning, receiving IMF interim funding
Changes to version 1.1	
EXA1a_v1.0 ,EXA1b_v1.0	Recommended for the IMF
VOX1a_v1.0 , TAF1a _v1.0	Removed from the list
Changes to version 1.2	
IPT1_v1.0	Recommended for routine commissioning, receiving IMF interim funding
Changes to version 1.3	
ELAF1_v1.0	Recommended for routine commissioning, receiving IMF interim funding
EXA1a_v1.0 ,EXA1b_v1.0	Updated EXA1a questions Q4 & Q5; EXA1b Question 2&3 combined
Changes to version 1.4	
CRO1_v1.0	Recommended for routine commissioning, receiving IMF interim funding
ETR1a_v1.0, ETR1b _v1.0,EXA1a_v1.0 ,EXA1b_v1.0,ELAF1_v1.0 and IPT1_v1.0	Updated IDs
Changes to version 1.5	
UBL1_v1.0	Recommended for routine commissioning, receiving IMF interim funding
IPT1_v1.0	Removed from the list
Changes to version 1.6	
CRO1_v1.1	Updated CRO1 question 2 & added a new question.
Changes to version 1.7	
CRO1_v1.1	Removed from the list
Changes to version 1.8	
EXA2a_v1.0 ,EXA2b_v1.0	Recommended for the IMF
UBL1_v1.0	Removed from the list
Changes to version 1.9	
FEN1a_v1.0	Recommended for routine commissioning, receiving IMF interim funding
Changes to version 1.10	
STS1_v1.0	Recommended for routine commissioning, receiving IMF interim funding
ELAF1_v1.0	1 drugs/indications removed from the list
Changes to version 1.11	
RUX3_v1.0	Recommended for routine commissioning, receiving IMF interim funding
Changes to version 1.12	
LEN1_v1.0	Recommended for routine commissioning, receiving IMF interim funding